AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel, is conducting a Phase I study titled ‘A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours.’ The study aims to understand how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, which could be crucial for optimizing treatment regimens.
The intervention involves administering ceralasertib alongside single doses of Drug X, Drug Y, and Drug Z. Ceralasertib is given twice daily from Day 1 to Day 7, with Drug X administered on Days 5 and 22, and Drugs Y and Z on Days 7 and 28, respectively. This approach seeks to evaluate the interaction and effect of ceralasertib on these drugs.
The study follows an open-label, single-group design without masking, focusing on treatment as its primary purpose. Participants undergo a structured sequence of visits, including screening and follow-up, with a washout period between drug administrations to ensure accurate assessments.
Key dates for the study include its start on May 21, 2025, and the latest update on June 24, 2025. These dates are essential for tracking the study’s progress and ensuring timely data collection and analysis.
This study’s update could influence AstraZeneca’s stock performance by showcasing its commitment to advancing cancer treatment options. Positive outcomes might boost investor confidence, while the involvement of Parexel underscores the study’s industry significance. Competitors in the oncology sector will likely monitor these developments closely.
The study is currently recruiting, with ongoing updates available on the ClinicalTrials portal for those seeking further information.